Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma (NCT06896916)
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.
Who can join: Review the eligibility criteria below.
Location: Beverly Hills Cancer Center /ID# 266921 — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Beverly Hills Cancer Center /ID# 266921 — Beverly Hills, California
- Colorado Blood Cancer Institute /ID# 273751 — Denver, Colorado
- Washington University /ID# 266972 — St Louis, Missouri
- Rutgers Cancer Institute of New Jersey /ID# 266833 — New Brunswick, New Jersey
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282 — New York, New York
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230 — Hillsborough, North Carolina
- Swedish Medical Center - Seattle /ID# 268052 — Seattle, Washington
- Blacktown Hospital /ID# 265983 — Blacktown, New South Wales
- Wollongong Hospital /ID# 265625 — Wollongong, New South Wales
- The Alfred Hospital /ID# 265981 — Melbourne, Victoria
- Austin Hospital /ID# 265984 — Melbourne, Victoria
- Sir Charles Gairdner Hospital /ID# 265985 — Nedlands, Western Australia
- University Health Network_Princess Margaret Cancer Centre /ID# 275636 — Toronto, Ontario
- Jewish General Hospital /ID# 267574 — Montreal, Quebec
- Chu de Nice-Hopital Larchet Ii /Id# 266845 — Nice, Alpes-Maritimes
- Hôpital La Timone /ID# 267053 — Marseille, Bouches-du-Rhone
- Chu De Lille - Hopital Claude Huriez /ID# 270193 — Lille, Hauts-de-France
- Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694 — Tours, Indre-et-Loire
- IUCT Oncopole /ID# 266391 — Toulouse, Occitanie
- National Cancer Center Hospital East /ID# 268343 — Kashiwa-shi, Chiba
- Kumamoto University Hospital /ID# 270530 — Kumamoto, Kumamoto
- Dokkyo Medical University Hospital /ID# 271648 — Mibu, Tochigi
- Nippon Medical School Hospital /ID# 270254 — Bunkyo-ku, Tokyo
- The Cancer Institute Hospital Of JFCR /ID# 268342 — Koto-ku, Tokyo
- Amsterdam UMC, Location VUmc /ID# 267670 — Amsterdam, North Holland
📞 Contact the Study Coordinator
Phone: (844) 663-3742
Email: abbvieclinicaltrials@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.